-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
89bio, Inc. (NASDAQ:ETNB) Short Interest Update
89bio, Inc. (NASDAQ:ETNB) Short Interest Update
89bio, Inc. (NASDAQ:ETNB – Get Rating) was the recipient of a significant decrease in short interest during the month of December. As of December 30th, there was short interest totalling 4,430,000 shares, a decrease of 7.1% from the December 15th total of 4,770,000 shares. Based on an average trading volume of 911,000 shares, the days-to-cover ratio is presently 4.9 days.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $34.00 price objective (up previously from $27.00) on shares of 89bio in a report on Monday, November 14th. Royal Bank of Canada dropped their price objective on shares of 89bio from $35.00 to $29.00 and set an "outperform" rating for the company in a report on Friday, November 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.25.
Get 89bio alerts:89bio Trading Down 1.1 %
NASDAQ:ETNB traded down $0.14 on Tuesday, reaching $12.15. 808,300 shares of the stock traded hands, compared to its average volume of 859,320. 89bio has a 1-year low of $2.00 and a 1-year high of $12.95. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.81 and a current ratio of 5.81. The company's 50 day moving average is $10.12 and its 200-day moving average is $7.34.
89bio (NASDAQ:ETNB – Get Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.32. Research analysts expect that 89bio will post -2.65 earnings per share for the current fiscal year.Insider Transactions at 89bio
In other news, CFO Ryan Martins sold 5,947 shares of the stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $12.51, for a total value of $74,396.97. Following the completion of the transaction, the chief financial officer now owns 36,368 shares of the company's stock, valued at $454,963.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 11.80% of the company's stock.
Institutional Trading of 89bio
Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in shares of 89bio during the 3rd quarter worth approximately $96,000. Captrust Financial Advisors acquired a new stake in 89bio in the 3rd quarter valued at $60,000. Jane Street Group LLC acquired a new stake in 89bio in the 3rd quarter valued at $115,000. State Street Corp grew its position in 89bio by 104.2% in the 3rd quarter. State Street Corp now owns 62,910 shares of the company's stock valued at $364,000 after purchasing an additional 32,100 shares during the period. Finally, Orchard Capital Management LLC grew its position in 89bio by 227.5% in the 3rd quarter. Orchard Capital Management LLC now owns 551,879 shares of the company's stock valued at $3,195,000 after purchasing an additional 383,386 shares during the period. Institutional investors and hedge funds own 87.78% of the company's stock.
About 89bio
(Get Rating)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Recommended Stories
- Get a free copy of the StockNews.com research report on 89bio (ETNB)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.
89BioInc.(納斯達克代碼:ETNB-GET Rating)是12月份空頭股數銷量大幅下降的接收方。截至12月30日,空頭股數共有443萬股,比12月15日的477萬股減少了7.1%。以911,000股的平均成交量計算,目前的天數與回補比率為4.9天。
華爾街分析師預測經濟增長
一些研究分析師最近發佈了關於該股的報告。康託·菲茨傑拉德在11月14日週一的一份報告中重申了對89Bio的增持評級,併發布了每股34.00美元的目標價(此前為27.00美元)。在11月11日星期五的一份報告中,加拿大皇家銀行將89Bio的股票目標價從35.00美元下調至29.00美元,並為該公司設定了“跑贏大盤”的評級。七位投資分析師對該股的評級為買入,一位分析師對該股的評級為買入。根據MarketBeat的數據,該股目前的共識評級為買入,共識目標價為25.25美元。
到達89Bio警報:89Bio股價下跌1.1%
納斯達克:etnb週二下跌0.14美元,至12.15美元。該股共有808,300股易手,而其平均成交量為859,320股。89Bio的一年低點為2.00美元,一年高位為12.95美元。該公司的負債權益比率為0.08,速動比率為5.81,流動比率為5.81。該公司的50日移動均線切入位在10.12美元,200日移動均線切入位在7.34美元。
89Bio(納斯達克代碼:ETNB-GET Rating)上一次公佈季度收益數據是在11月10日星期四。該公司公佈本季度每股收益(0.57美元),比普遍預期的(0.89美元)高出0.32美元。研究分析師預計,89Bio本財年的每股收益將達到2.65美元。89Bio的內幕交易
在其他新聞方面,首席財務官瑞安·馬丁斯在1月3日星期二的交易中出售了5947股該公司股票。這些股票的平均價格為12.51美元,總價值為74,396.97美元。交易完成後,首席財務官現在擁有該公司36,368股股票,價值454,963.68美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,可以通過以下方式獲取此超鏈接。公司內部人士持有該公司11.80%的股份。
89Bio的機構交易
幾家大型投資者最近調整了對該股的持股比例。紐約梅隆銀行(Bank Of New York Mellon Corp)在第三季度收購了89Bio股權,價值約9.6萬美元。CapTrust Financial Advisors在第三季度收購了89Bio的新股份,價值6萬美元。建恩街集團(Jane Street Group LLC)在第三季度以11.5萬美元的價格收購了89io的新股份。道富銀行在第三季度的持倉增加了104.2%。道富銀行目前持有62,910股該公司股票,價值364,000美元,在此期間又購買了32,100股。最後,Orchard Capital Management LLC在第三季度將其在89Bio的頭寸增加了227.5%。Orchard Capital Management LLC現在擁有該公司551,879股股票,價值3,195,000美元,在此期間又購買了383,386股。機構投資者和對沖基金持有該公司87.78%的股票。
約89Bio
(獲取評級)
89BioInc.是一家臨床階段的生物製藥公司,專注於治療肝臟和心臟代謝性疾病的療法的開發和商業化。它的主要候選產品是pegozafermin,一種用於治療非酒精性脂肪性肝炎的成纖維細胞生長因數21的糖基化類似物。
推薦故事
- 免費獲取股票新聞網站89Bio(ETNB)上的研究報告
- Intuit即將採取行動,但走哪條路呢?
- 1月下旬收益表現出流行音樂的潛力
- 低價股仍在派發股息
- 為什麼Chipotle的股價本週飆升?
- 諾斯羅普·格魯曼公司的拋售是一個機會嗎?
接受89Bio日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對89Bio和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧